|
|
 |
Candin® Skin Test Antigen |
| Candin is indicated for use in the assessment of cell mediated immunity in persons where anergy may be a factor. |
| Candin® is the only FDA licensed DTH skin test antigen made from Candida albicans. It is potency standardized by DTH skin testing in humans. The product is indicated in the assessment of immune responsiveness in clinical situations involving the cellular immune system. Intact cell-mediated immunity (CMI) requires a complex interaction between lymphocytes, macrophages and cytokines. Various immune disorders and disease processes can alter the CMI response. These include congenital immunodeficiencies, acquired immunodeficiencies, cancer, malnutrition and viral and fungal diseases. A positive DTH response to Candin® indicates that the CMI is functioning properly. Candin® is frequently used as a control for tuberculin skin testing to rule out anergy as a possible factor in persons who are skin-test negative to tuberculin. For full prescribing information see insert. |
| The use of anergy controls, such as CANDIN®, provides a basis for interpreting the delayed type hypersensitivity (DTH) response to PPD in patients whose cellular immunity is compromised (anergy). Compromised patients can register false negatives during TB testing, making diagnosis much more complicated. 1, 2, 3, 4 |
- McMurry, D.N. and Echeverria, A., Cell-Mediated Immunity in Anergic Patients with Pulmonary Tuberculosis. Am. Rev. Resp. Dis., 118: 827, 1978.
- Creditor, M.C., et. al., Tuberculosis, Tuberculin Reactivity, and Delayed Cutaneous Hypersensitivity in Nursing Home Residents. J. Gerontology, 43:M97, 1988.
- Selwyn, P.A., et al., High Risk of Active Tuberculosis in HIV-Infected Drug Users with Cutaneous Anergy. JAMA, 268: 504, 1992.
- Nachman, S.A. and Navaie-Waliser, M., Tuberculin Skin Testing in a Pediatric Population Exposed to Human Immunodeficiency Virus. Ped. Infect. Dis. J. 15:1041, 1996.
|
|
